You are here

  • Home
  • Archive
  • Volume 77, Issue 4
  • Application of the 2015/2016 EULAR recommendations for cardiovascular risk in daily practice: data from an observational study

Article Text

Article menu
Download PDFPDF
Letter
Application of the 2015/2016 EULAR recommendations for cardiovascular risk in daily practice: data from an observational study
  1. Claire Immediato Daïen1,2,
  2. Amandine Tubery1,
  3. Guilhem du Cailar3,
  4. Thibault Mura4,
  5. François Roubille5,
  6. Jacques Morel1,2,
  7. Jean Bousquet6,
  8. Pierre Fesler3,
  9. Bernard Combe1,2
  1. 1 Department of Rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
  2. 2 Institute of Molecular Genetics, Montpellier, France
  3. 3 Internal Medicine and Hypertension, Lapeyronie Hospital and Montpellier University, Montpellier, France
  4. 4 Department of Medical Information, Montpellier University, Montpellier, France
  5. 5 Department of Cardiology, Arnaud de Villeneuve Hospital and Montpellier University, Montpellier, France
  6. 6 University Hospital, Montpellier, France
  1. Correspondence to Claire Immediato Daïen, Department of Rheumatology, Hôpital Lapeyronie, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France; cidaien{at}gmail.com

http://dx.doi.org/10.1136/annrheumdis-2017-211074

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    The European League Against Rheumatism (EULAR) recently updated the recommendations for cardiovascular disease (CVD) risk management in patients with rheumatoid arthritis (RA).1 In contrast to the 2009 recommendations which advised to multiply by 1.5 the global CVD risk in the presence of certain RA-specific criteria,2 the 2015/2016 update recommends to multiply by 1.5 the global CVD risk for all patients with RA. It also considers the use of carotid ultrasound to screen asymptomatic atherosclerotic plaques. Indeed, the majority of the CVD events occur in the ‘low’ and ‘intermediate’ risk groups and carotid plaque detection to classify patients improves cardiovascular risk prediction.3 The European Society of Cardiology guidelines classify patients with carotid plaque at very high CVD risk.4 Immediate statin use is indicated in those patients if low-density lipoprotein cholesterol is ≥0.7 g/L.4 In a post hoc analysis, we evaluated the impact of the updated 2015/2016 EULAR CVD recommendations …

    View Full Text

    Footnotes

    • Contributors Conceptualisation: CID, JM, PF, JB, BC. Methodology: CID, PF, FR, TM. Software: TM, CID, PF. Formal analysis: CID, AT, TM. Investigation: CID, AT, GdC, JM, BC, PF, FR. Resources: CID, JM, PF, JB, BC. Writing (original draft preparation): CID, AT. Writing (review and editing): JB, FR, GdC, JM, BC, TM, PF. Supervision: CID, BC, PF, JB. Project administration: CID, BC, PF, JB.

    • Funding MACVIA-LR.

    • Competing interests CID has received honoraria from BMS, MSD, Pfizer, Roche-Chugai, and UCB, and research grants from MSD, Pfizer, Roche-Chugai and UCB. PLEASE REPORT SIMILAR COMPETING INTEREST AT THE END OF THE MANUSCRIPT

    • Provenance and peer review Not commissioned; externally peer reviewed.